no the point isnt missed here - remember their trial patients got chemo AND device together - if you took the same type of patients as those enrolled in the OSL trial and gave them the same chemo that the Panco patients got, but NOT the device there is data showing you’d still be able to “convert” 20-30%, and in those 20-30% converted and resected, you’d expect survival >30 months median - that’s what is meant by “neoadjuvant” therapy - I’m not saying theIr results are bad, it’s just that they don’t prove device added anything over the chemo to allowed more to get tumour removed than they’d otherwise have got with the neoadjuvant chemo given on its own. Even OSL have just confirmed that in their ASX release!
OSL Price at posting:
14.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)